ER

Bayer submits NDA for radium Ra 223 dichloride for castration-resistant prostate cancer

Friday, December 14, 2012 12:07 PM

Bayer HealthCare has submitted a New Drug Application (NDA) to the FDA seeking approval for radium Ra 223 dichloride (radium-223), a fast tracked investigational compound for the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases.

More... »

The Medicines Company to acquire Incline Therapeutics

Friday, December 14, 2012 10:14 AM

The Medicines Company, a medical solutions company based in Parsippany, N.J., has agreed to acquire Incline Therapeutics, hospital-focused specialty pharmaceutical company based in Redwood City, Calif.

More... »

Insero Health completes phase I trial in drug resistant epilepsy

Thursday, December 13, 2012 08:00 AM

Insero Health, a clinical-stage company that develops small molecule therapies derived from natural products to treat neurological diseases, has completed a phase Ib trial of its lead compound INS001 in patients with drug-resistant epilepsy. 

More... »

Galderma to acquire Spirig Pharma

Wednesday, December 12, 2012 02:31 PM

Galderma Pharma, a Switzerland-based global specialty pharmaceutical company focused on dermatology, has entered into a definitive agreement to acquire Spirig Pharma, a Swiss company that develops, produces, and markets dermatological products.

More... »

Chiltern welcomes Cedric Burg and James Gunter

Wednesday, December 12, 2012 11:29 AM

Chiltern International, a global CRO, has appointed Dr. Cedric Burg and James Gunter to their team.

More... »

GSK, Fred Hutchinson Cancer Research Center to develop muscular dystrophy therapeutics

Wednesday, December 12, 2012 10:19 AM

Fred Hutchinson Cancer Research Center and global healthcare company GlaxoSmithKline (GSK) have formed a partnership to develop therapeutics to treat an inherited form of muscular dystrophy.

More... »

Pernix Therapeutics to acquire Somaxon Pharmaceuticals

Wednesday, December 12, 2012 09:22 AM

Pernix Therapeutics, a specialty pharmaceutical company based in The Woodlands, Texas, has entered into a definitive merger agreement to acquire Somaxon Pharmaceuticals, a San Diego-based specialty pharmaceutical company, in a stock-for-stock transaction with a total equity value of $25 million.

More... »

INC Research strengthens leadership for strategic advisory services unit

Monday, December 10, 2012 01:44 PM

INC Research, a therapeutically focused CRO, has appointed Robert Ryan, PhD, as vice president of regulatory strategy, consulting and submissions. Ryan will provide global leadership to position INC Strategic Advisory Services as a market leader in regulatory consulting and submissions offerings.

More... »

TFS International acquires all shares of Dimensione Ricerca

Monday, December 10, 2012 12:26 PM

TFS International, a CRO based in Sweden, has signed an agreement to acquire Dimensione Ricerca, an independent clinical CRO based in Rome and Milan, Italy.

More... »

Perceptive Informatics opens first customer care office in China

Monday, December 10, 2012 10:46 AM

Perceptive Informatics, an e-Clinical solutions provider and subsidiary of PAREXEL International, has opened a customer care office in Shanghai to service biopharmaceutical researchers in China and Taiwan who are using Perceptive’s technology solutions.

More... »